Workflow
Regulus(RGLS)
icon
Search documents
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Prnewswire· 2025-01-29 12:00
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference c ...
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Prnewswire· 2024-11-26 13:00
SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Evercore 7th Annual HealthCONx Conference: Fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. ET Piper Sandler 36th Annual Healthcare Conference: Presentation on Wednesday, December 4, 2024, ...
Regulus(RGLS) - 2024 Q3 - Quarterly Report
2024-11-07 21:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |--------------------------------------------------------------------------------------|-------------------------------------------- ...
Regulus(RGLS) - 2024 Q3 - Quarterly Results
2024-11-07 21:16
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalen ...
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Prnewswire· 2024-11-07 21:05
Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-endEnded third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026SAN DIEGO, Nov. 7, 2024 / ...
Regulus(RGLS) - 2024 Q2 - Quarterly Report
2024-08-08 20:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |----------------------------------------------------------------------------|----------------------------------------------------------- ...
Regulus(RGLS) - 2024 Q2 - Quarterly Results
2024-08-08 20:16
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Of icer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO, August 8, 2024 – Regulus Therap ...
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Prnewswire· 2024-08-08 20:05
Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Officer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO, Aug. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the dis ...
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Prnewswire· 2024-08-06 12:00
SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th at 8:30 a.m. ET. A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of ...
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Prnewswire· 2024-07-09 12:00
SAN DIEGO, July 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ...